Immage Biotherapeutics Corp.

IMMG

US45250J1007

Commodity Chemicals

Market Closed - OTC Markets Other stock markets 03:55:53 2024-03-06 pm EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2017	ImMAGE Biotherapeutics Announces Termination of Operations	CI
2017	ImMAGE Biotherapeutics Initiates Repeat Toxicology Study for Lead Candidate, IMT-001	CI

Immage Biotherapeutics Corp. announced that it has received $0.5 million in funding from Coventry International Limited

March 08, 2016

ImMAGE Biotherapeutics Corporation announced that it has received $500,000 in seed round of funding from existing investor Coventry International Limited on March 9, 2016.

Latest news about Immage Biotherapeutics Corp.

ImMAGE Biotherapeutics Announces Termination of Operations	17-08-31	CI
ImMAGE Biotherapeutics Initiates Repeat Toxicology Study for Lead Candidate, IMT-001	17-05-04	CI
Immage Biotherapeutics Corp. Announces its Immunotherapy Successfully Passed Early Toxicology and Efficacy Studies	17-03-27	CI
Immage Biotherapeutics Corp. Auditor Raises 'Going Concern' Doubt	16-12-07	CI
Immage Biotherapeutics Corp. announced that it has received $0.5 million in funding from Coventry International Limited	16-03-08	CI
Immage Biotherapeutics Corp. Auditor Raises 'Going Concern' Doubt	15-11-03	CI
Epicure Charcoal, Inc. Announces Board Changes	15-05-15	CI
Coventry International Limited acquired a 59.94% stake in Epicure Charcoal, Inc. from William Alex Robertson.	15-05-15	CI

Chart Immage Biotherapeutics Corp.

Duration

Period

More charts

Immage Biotherapeutics Corp. is a biotechnology company. The Company is engaged in developing cancer immunotherapy through development of cutting-edge immunotherapy candidates using bioinformatics and outsourced laboratory resources. It is focused on developing immunotherapy biologics to treat various cancers. The Company develops, markets and licenses its immunotherapy candidate for melanoma-associated antigen-A (MAGE A). The Company plans to focus on the development of immunotherapy for breast and prostate cancer. The Company focuses on developing a fusion/hybrid antigen cancer vaccine that would not only be human leukocyte antigen (HLA) free, but also be effective to all the isomers associated with MAGE A, from 1 to 11, and the identification and development of immunotherapy candidates from its intellectual property library for the preparation for human clinical trials using a viral vector construct.

Sector

Commodity Chemicals

More about the company

Sector Other Commodity Chemicals

	1st Jan change	Capi.
IMMAGE BIOTHERAPEUTICS CORP.	-.--%	151
AIR LIQUIDE	+5.14%	103B
SAUDI BASIC INDUSTRIES CORPORATION	-1.80%	65.6B
PT CHANDRA ASRI PACIFIC TBK	+39.52%	39.06B
WANHUA CHEMICAL GROUP CO., LTD.	+12.91%	37.58B
LYONDELLBASELL INDUSTRIES N.V.	+7.41%	33.26B
WESTLAKE CORPORATION	+6.85%	19.22B
NINGXIA BAOFENG ENERGY GROUP CO., LTD.	+12.86%	16.83B
RONGSHENG PETROCHEMICAL CO., LTD.	+7.73%	15.03B
HENGLI PETROCHEMICAL CO.,LTD.	+16.93%	14.96B

Other Commodity Chemicals